{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-beta+%28IFN-beta%29&page=6",
    "query": {
      "intervention": "Interferon-beta (IFN-beta)",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 128,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-beta+%28IFN-beta%29&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-beta+%28IFN-beta%29&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:56:27.547Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03344094",
      "title": "Mechanism of Action of Ocrelizumab in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-02-23",
      "completion_date": "2019-04-10",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03344094"
    },
    {
      "nct_id": "NCT03865212",
      "title": "Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Choroid Melanoma",
        "Metastatic Melanoma",
        "Metastatic Mucosal Melanoma",
        "Metastatic Uveal Melanoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-06-12",
      "completion_date": "2025-10-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03865212"
    },
    {
      "nct_id": "NCT00324506",
      "title": "Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil (CellCept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 43,
      "start_date": "2006-05",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 3,
      "location_summary": "Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas",
      "locations": [
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324506"
    },
    {
      "nct_id": "NCT00630721",
      "title": "Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "IFNbeta-1b",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 56,
      "start_date": "2007-09",
      "completion_date": "2011-03-15",
      "has_results": false,
      "last_update_posted_date": "2018-10-18",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00630721"
    },
    {
      "nct_id": "NCT03284970",
      "title": "Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-08-23",
      "completion_date": "2018-05-11",
      "has_results": false,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 1,
      "location_summary": "Foxborough, Massachusetts",
      "locations": [
        {
          "city": "Foxborough",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03284970"
    },
    {
      "nct_id": "NCT04278404",
      "title": "Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronavirus Infection (COVID-19)",
        "Pulmonary Arterial Hypertension",
        "Urinary Tract Infections in Children",
        "Hypertension",
        "Pain",
        "Hyperphosphatemia",
        "Primary Hyperaldosteronism",
        "Edema",
        "Hypokalemia",
        "Heart Failure",
        "Hemophilia",
        "Menorrhagia",
        "Insomnia",
        "Pneumonia",
        "Skin Infection",
        "Arrythmia",
        "Asthma in Children",
        "Bronchopulmonary Dysplasia",
        "Adrenal Insufficiency",
        "Fibrinolysis; Hemorrhage",
        "Attention Deficit Hyperactivity Disorder",
        "Multisystem Inflammatory Syndrome in Children (MIS-C)",
        "Kawasaki Disease",
        "Coagulation Disorder",
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "0 Years to 20 Years"
      },
      "enrollment_count": 5000,
      "start_date": "2020-03-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 49,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04278404"
    },
    {
      "nct_id": "NCT03120624",
      "title": "VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Endometrial Carcinoma",
        "Recurrent Endometrial Adenocarcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Endometrial Clear Cell Adenocarcinoma",
        "Recurrent Endometrial Endometrioid Adenocarcinoma",
        "Recurrent Endometrial Mixed Cell Adenocarcinoma",
        "Recurrent Endometrial Serous Adenocarcinoma",
        "Recurrent Endometrial Undifferentiated Carcinoma",
        "Recurrent Uterine Corpus Carcinosarcoma",
        "Stage IV Uterine Corpus Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorine F 18 Tetrafluoroborate",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ruxolitinib Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Technetium Tc-99m Sodium Pertechnetate",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2017-09-15",
      "completion_date": "2028-01-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03120624"
    },
    {
      "nct_id": "NCT00146068",
      "title": "EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Avonex/Zocor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-09",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-05",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146068"
    },
    {
      "nct_id": "NCT00428584",
      "title": "RNF and Betaseron® Tolerability Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis (RRMS)"
      ],
      "interventions": [
        {
          "name": "New Formulation of rebif - human interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta -1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 129,
      "start_date": "2006-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428584"
    },
    {
      "nct_id": "NCT00085670",
      "title": "Cytokine Gene Polymorphisms in Bone Marrow Failure",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bone Marrow Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "2 Years to 80 Years"
      },
      "enrollment_count": 79,
      "start_date": "2005-02-11",
      "completion_date": "2007-03-14",
      "has_results": false,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-11-15T13:56:27.547Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085670"
    }
  ]
}